TickerFacts.

Nexgel, Inc. (NXGL): Cost of Revenue

Annual figures by period end, from SEC filings.

Restated years: each year's figure is from the latest filing that reports it. The company later restated the year ended 2023-12-31 (for example after a spin-off or a discontinued operation), while the year before it was last reported on the old basis. Changes across those points are marked n/c (not comparable), and growth rates are not computed across them.

$6.91M
Year ended 2025-12-31
$7.83M
Trailing 12 months to 2026-06-30
2018-12-31: $1.70M2019-12-31: $854.0K2020-12-31: $965.0K2021-12-31: $1.54M2022-12-31: $1.79M2023-12-31: $3.71M2024-12-31: $5.94M2025-12-31: $6.91M$6.91M
2018-12-31 Cost of Revenue (USD) 2025-12-31
Period endedCost of RevenueChange YoYSource filing
2025-12-31$6.91M+16.4%2026-03-31, From 2025-01-01
2024-12-31$5.94M+59.9%2026-03-31, From 2024-01-01
2023-12-31$3.71Mn/c2025-03-27, From 2023-01-01
2022-12-31$1.79M+16.1%2024-04-10, From 2022-01-01
2021-12-31$1.54M+59.9%2023-03-28, From 2021-01-01
2020-12-31$965.0K+13.0%2022-03-21, From 2020-01-01
2019-12-31$854.0K-49.7%2021-03-31, From 2019-01-01
2018-12-31$1.70Mn/a2020-04-03, From 2018-01-01

Cost of Revenue at similar companies

Companies with the same SEC industry code (Surgical & Medical Instruments & Apparatus), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCost of RevenueChange YoY
Nexgel, Inc. (NXGL)2025-12-31$6.91M+16.4%
Medinotec Inc. (MDNC)2026-02-28$4.60M+7.1%
Neuroone Medical Technologies Corp (NMTC)2025-09-30$3.96M+66.7%
InspireMD, Inc. (NSPR)2025-12-31$6.33M+15.0%
Allurion Technologies, Inc. (ALUR)2025-12-31$5.66M-46.6%
Biotricity Inc. (BTCY)2026-03-31$3.05M-5.5%
Profound Medical Corp. (PROF)2025-12-31$4.71M+29.2%
Beyond Air, Inc. (XAIR)2026-03-31$7.43M+38.4%
Vivos Therapeutics, Inc. (VVOS)2025-12-31$6.90M+14.8%

Compare NXGL, MDNC, NMTC, NSPR side by side · Screen every company in Surgical & Medical Instruments & Apparatus ↗